Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

Patent Broadens Immunogenic Compositions for Preventive Vaccine Approach

SAN JOSE, Calif., April 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new patent related to the Company's innovative breast cancer vaccine technology. The patent along with others related to this technology, has been exclusively licensed to Anixa Biosciences, by Cleveland Clinic. The patent will expand the scope of immunogenic compositions utilized in Anixa's breast cancer vaccine.

Read more at prnewswire.com